Clinical events after cessation of lamivudine therapy inpatients recovered from hepatitis b flare with hepaticdecompensation

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 5, 2015, Pages 979-986

  Chang, Ming Ling ^a   Jeng, Wen Juei ^a   Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Antiviral therapy; Cirrhosis; Liver cancer; Nucleos(t)ide analog

Indexed keywords

LAMIVUDINE; ANTIVIRUS AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; COHORT ANALYSIS; COMPLICATION; HEPATITIS B, CHRONIC; LIVER FAILURE; MIDDLE AGED; PATHOLOGY; TREATMENT WITHDRAWAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER FAILURE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84927909954     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.10.023     Document Type: Article

References (35)

1. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
2. Chu C.M., Liaw Y.F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006, 26:142-152.
3. Peng C.Y., Chien R.N., Liaw Y.F. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. JHepatol 2012, 57:442-450.
4. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
5. Liaw Y.F., Kao J.H., Piratvisuth T., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
6. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. JHepatol 2012, 57:167-185. European Association for the Study of the Liver.
7. Lampertico P., Viganò M., Colombo M. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?. Liver Int 2013, 33(Suppl 1):157-163.
8. Locarnini S., Zoulim F. Molecular genetics of HBV infection. Antivir Ther 2010, 15(Suppl 3):3-14.
9. Chotiyaputta W., Peterson C., Ditah F.A., et al. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. JHepatol 2011, 54:12-18.
10. Han S.H., Jing W., Mena E., et al. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy. JMed Econ 2012, 15:1159-1166.
11. Jeng W.J., Sheen I.S., Chen Y.C., et al. Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients. Hepatology 2013, 58:1888-1896.
12. Sheen I.S., Liaw Y.F., Tai D.I., et al. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985, 89:732-735.
13. Chien R.N., Lin C.H., Liaw Y.F. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. JHepatol 2003, 38:322-327.
14. Liaw Y.F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. JGastroenterol Hepatol 2003, 18:246-252.
15. Liaw Y.F., Tai D.I., Chu C.M., et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493-496.
16. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022. American Association for the Study of Liver Diseases.
17. Hosaka T., Suzuki F., Kobayashi M., et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013, 58:98-107.
18. Niro G.A., Ippolito A.M., Fontana R., et al. Long-term outcome of hepatitis B virus-related chronic hepatitis under protracted nucleos(t)ide analogues. JViral Hepat 2013, 20:502-509.
19. Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized open-label study. Hepatology 2011, 54:91-100.
20. Liaw Y.F., Sheen I.S., Lee C.M., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53:62-72.
21. Lim S.G., Aung M.O., Chung S.W., et al. Patient preferences for hepatitis B therapy. Antivir Ther 2013, 18:663-670.
22. Hadziyannis S.J., Sevastianos V., Rapti I., et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012, 143:629-636.
23. Liu F., Wang L., Li X.Y., et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. JGastroenterol Hepatol 2011, 26:456-460.
24. Ha M., Zhang G., Diao S., et al. Aprospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol 2012, 157:285-290.
25. Locarnini S., Zoulim F. Molecular genetics of HBV infection. Antivir Ther 2010, 3(Suppl):3-14.
26. Levrero M., Pollicino T., Petersen J., et al. Control of cccDNA function in hepatitis B virus infection. JHepatol 2009, 51:581-592.
27. Fattovich G., Bortolotti F., Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. JHepatol 2008, 48:335-352.
28. Chen Y.C., Jeng W.J., Chien R.N., et al. Hepatocellular carcinoma development in HBe-negative hepatitis B cirrhotic patients with entecavir treatment. JHepatol 2013, 58:S214.
29. Lin D.Y., Sheen I.S., Chiu C.T., et al. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. JClin Ultrasound 1993, 21:303-308.
30. Liaw Y.F. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011, 53:2121-2129.
31. Chu C.M., Yeh C.T., Lee C.S., et al. Procore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. JClin Microbiol 2002, 40:16-21.
32. Tsai W.L., Lo G.H., Hsu P.I., et al. Role of genotype and precore/basal core promoter mutations of hepatitis B virus in patients with chronic hepatitis B with acute exacerbation. Scand J Gastroenterol 2008, 43:196-201.
33. Pol S., Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. JViral Hepat 2012, 19:377-386.
34. Liaw Y.F. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. JHepatol 2009, 51:403-410.
35. Arama V., Leblebicioglu H., Simon K., et al. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther 2014, 19:245-257.